Marvel Biosciences’ Lead Drug Candidate MB-204 Demonstrated a 400% Survival Rate Increase in Animals Treated with the Cancer Treatment Cisplatin

Calgary, Alberta–(November 22, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that in a recent study done by the Company, its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment,...

Marvel Biosciences Lead Drug Candidate MB-204 Demonstrated Superior Anti-Anxiety Activity Over FDA-Approved Istradefylline in Head-to-Head Pre-clinical Studies

Calgary, Alberta–(November 14, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that in a pre-clinical test for anxiety, its lead drug candidate MB-204, a fluorinated derivative of Istradefylline, out-performed Istradefylline in a head-to-head pre-clinical and in depressive...

Marvel Biosciences’ Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer’s Disease and Depression

Marvel Biosciences’ Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer’s Disease and Depression Calgary, Alberta–(November 7, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), announced today that in a pre-clinical mouse study conducted by the Company, its lead...

Marvel Biosciences Successfully Completes Engineering Run of Its Lead Asset Targeting Alzheimer’s Further Advancing Towards FDA Phase I Human Trials

Calgary, Alberta–(November 1, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), announces it has successfully completed a large-scale engineering run of its novel solid amorphous dispersion (SAD) formulation of MB-204 by Zhejiang Ausun Pharmaceutical Co., Ltd. (“Ausun”). The engineering run material...

Marvel Biosciences Advances Closer to Human Trials after the Successful Completion of a Second Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies

 CALGARY, Alberta – (October 25, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study in dogs for its product MB-204, further validating the Company’s lead drug candidate low toxicity characteristic.   "We have now completed and further validated MB-204’s safety profile through this...

Marvel Biosciences Successfully Completes Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies

CALGARY, Alberta – (October 17, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study for its product MB-204, validating its low toxicity.   MB-204 is the Company’s lead compound and is a novel fluorinated form of Istradefylline (FDA approved anti-Parkinson’s disease drug) and is a blood...

Marvel Biosciences Highlights Recent Research on the Serotonin Theory of Depression

CALGARY, Alberta – (October 3, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) highlights recent a meta-analysis which re-evaluated the strength of the link between serotonin levels and depression.   According to the study published in Nature Molecular Psychiatry on July 20, 2022 1, despite the influence of the serotonin theory of depression, there was no...

Marvel Biosciences Announces Stock Option Grants

Calgary, Alberta, Canada, September 26, 2022 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to certain directors and officers to acquire an aggregate of 1,425,000 common shares in the capital...

Marvel Biosciences Highlights Recent Research on Link Between NASH and Alzheimer’s Disease

CALGARY, Alberta – (August 31, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer’s Disease (AD), two programs its lead asset, MB-204 are targeting.   A five-year longitudinal study in Sweden tracked subjects with and without NASH over the age of 65, and those with...

Marvel Biosciences Corp. Closes Second Tranch of Private Placement

Calgary, Alberta, Canada, August 9, 2022 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or“Marvel”), is pleased to report that, further to its news releases of June 21, 2022 and July 18, 2022, it has closed its non-brokered private placement of 7,200,000 units of the Company (the “Units”) at a price of $0.10 per...